Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/56777
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? |
Author: | Yazbek, R. Howarth, G. Abbott, C. |
Citation: | Trends in Pharmacological Sciences, 2009; 30(11):600-607 |
Publisher: | Elsevier Science London |
Issue Date: | 2009 |
ISSN: | 0165-6147 1873-3735 |
Statement of Responsibility: | Roger Yazbeck, Gordon S. Howarth and Catherine A. Abbott |
Abstract: | Dipeptidyl peptidase (DPP)-4 is a member of the S9b serine protease family, which also includes DPP8 and DPP9. DPP4 cleaves a number of regulatory factors, including chemokines and growth factors. DPP4 inhibitors have recently emerged as an effective treatment option for type 2 diabetes. Early in vitro studies demonstrated that DPP4 inhibitors inhibit T-cell proliferation and cytokine production, leading to their investigation in numerous pre-clinical models of inflammatory diseases, including arthritis, multiple sclerosis and inflammatory bowel disease. Recent data suggest that the early DPP4-specific inhibitors might also bind DPP8 and DPP9, thus exerting their effects through non-specific binding. This review highlights recent insights into the applicability of DPP inhibitors as novel pharmacological agents for inflammatory disease. |
Keywords: | Animals Humans Inflammation Dipeptidases Drug Delivery Systems Drug Evaluation, Preclinical Clinical Trials as Topic Dipeptidyl-Peptidase IV Inhibitors Dipeptidyl-Peptidases and Tripeptidyl-Peptidases Dipeptidyl Peptidase 4 |
Description: | Copyright © 2009 Elsevier Ltd. All rights reserved. |
DOI: | 10.1016/j.tips.2009.08.003 |
Published version: | http://dx.doi.org/10.1016/j.tips.2009.08.003 |
Appears in Collections: | Agriculture, Food and Wine publications Aurora harvest 5 |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.